Neuphoria Therapeutics (NEUP) Non-Current Assets (2021 - 2026)

Neuphoria Therapeutics (NEUP) has 6 years of Non-Current Assets data on file, last reported at $13.2 million in Q1 2026.

• Quarterly Non-Current Assets fell 3.46% year-over-year to $13.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $53.3 million (down 5.38% YoY) and the FY2025 annual result came in at $13.5 million, down 6.27% from the prior year.
• Non-Current Assets held at $13.2 million in Q1 2026 per NEUP's latest filing, from $13.2 million in the prior quarter.
• Across five years, Non-Current Assets topped out at $16.8 million in Q2 2022 and bottomed at $13.2 million in Q1 2026.
• The 5-year median for Non-Current Assets is $13.7 million (2024), against an average of $14.2 million.
• The widest annual swing landed in 2023, when Non-Current Assets decreased 9.04%; it then slipped 3.46% in 2026.
• Tracing NEUP's Non-Current Assets over 5 years: stood at $16.8 million in 2022, then fell by 9.04% to $15.3 million in 2023, then retreated by 10.07% to $13.8 million in 2024, then dropped by 4.05% to $13.2 million in 2025, then retreated by 0.45% to $13.2 million in 2026.
• Per Business Quant, the three latest NEUP Non-Current Assets figures stand at $13.2 million (Q1 2026), $13.2 million (Q4 2025), and $13.4 million (Q3 2025).

Peer Comparison